» Articles » PMID: 23479355

Identification of Small Molecules That Inhibit the Interaction of TEM8 with Anthrax Protective Antigen Using a FRET Assay

Overview
Journal J Biomol Screen
Publisher Sage Publications
Date 2013 Mar 13
PMID 23479355
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Tumor marker endothelial 8 (TEM8) is a receptor for the protective antigen (PA) component of anthrax toxin. TEM8 is upregulated on endothelial cells lining the blood vessels within tumors, compared with normal blood vessels. A number of studies have demonstrated a pivotal role for TEM8 in developmental and tumor angiogenesis. We have also shown that targeting the anthrax receptors with a mutated form of PA inhibits angiogenesis and tumor formation in vivo. Here we describe the development and testing of a high-throughput fluorescence resonance energy transfer assay to identify molecules that strongly inhibit the interaction of PA and TEM8. The assay we describe is sensitive and robust, with a Z' value of 0.8. A preliminary screen of 2310 known bioactive library compounds identified ebselen and thimerosal as inhibitors of the TEM8-PA interaction. These molecules each contain a cysteine-reactive transition metal, and complementary studies indicate that their inhibition of interaction is due to modification of a cysteine residue in the TEM8 extracellular domain. This is the first demonstration of a high-throughput screening assay that identifies inhibitors of TEM8, with potential application for antianthrax and antiangiogenic diseases.

Citing Articles

AZIN1 RNA editing alters protein interactions, leading to nuclear translocation and worse outcomes in prostate cancer.

Ghalali A, Wang L, Stopsack K, Rice J, Wu S, Wu C Exp Mol Med. 2022; 54(10):1713-1726.

PMID: 36202978 PMC: 9636422. DOI: 10.1038/s12276-022-00845-6.


Capillary morphogenesis gene 2 (CMG2) mediates growth factor-induced angiogenesis by regulating endothelial cell chemotaxis.

Cryan L, Tsang T, Stiles J, Bazinet L, Lee S, Garrard S Angiogenesis. 2022; 25(3):397-410.

PMID: 35212873 PMC: 9250616. DOI: 10.1007/s10456-022-09833-w.


Toxicology and pharmacology of synthetic organoselenium compounds: an update.

Nogueira C, Barbosa N, Rocha J Arch Toxicol. 2021; 95(4):1179-1226.

PMID: 33792762 PMC: 8012418. DOI: 10.1007/s00204-021-03003-5.


Selenium and selenoproteins in viral infection with potential relevance to COVID-19.

Zhang J, Saad R, Taylor E, Rayman M Redox Biol. 2020; 37:101715.

PMID: 32992282 PMC: 7481318. DOI: 10.1016/j.redox.2020.101715.


The selenium-containing drug ebselen potently disrupts LEDGF/p75-HIV-1 integrase interaction by targeting LEDGF/p75.

Zhang D, Yan H, Xu X, Xu L, Yin Z, Chang S J Enzyme Inhib Med Chem. 2020; 35(1):906-912.

PMID: 32228103 PMC: 7170385. DOI: 10.1080/14756366.2020.1743282.


References
1.
St Croix B, Rago C, Velculescu V, Traverso G, Romans K, Montgomery E . Genes expressed in human tumor endothelium. Science. 2000; 289(5482):1197-202. DOI: 10.1126/science.289.5482.1197. View

2.
Jinnin M, Medici D, Park L, Limaye N, Liu Y, Boscolo E . Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma. Nat Med. 2008; 14(11):1236-46. PMC: 2593632. DOI: 10.1038/nm.1877. View

3.
Fernando S, Fletcher B . Targeting tumor endothelial marker 8 in the tumor vasculature of colorectal carcinomas in mice. Cancer Res. 2009; 69(12):5126-32. DOI: 10.1158/0008-5472.CAN-09-0725. View

4.
Yamaguchi T, Sano K, Takakura K, Saito I, Shinohara Y, Asano T . Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial. Ebselen Study Group. Stroke. 1998; 29(1):12-7. DOI: 10.1161/01.str.29.1.12. View

5.
Nanda A, Carson-Walter E, Seaman S, Barber T, Stampfl J, Singh S . TEM8 interacts with the cleaved C5 domain of collagen alpha 3(VI). Cancer Res. 2004; 64(3):817-20. DOI: 10.1158/0008-5472.can-03-2408. View